Worch J, Rohde M, Burkhardt B. Mature B -

cell lymphoma and leukemia in children and

adolescents - review of standard chemotherapy

regimen and perspectives. Pediatr Hematol

Oncol. 2013;30(6):465-483.

Cunha KCCMS, Oliveira MCLA, Gomes ACS,

de Castro LPF, Viana MB. Clinical course and

prognostic factors of children with Burkitt’s

lymphoma in a developing country: the

experience of a single centre in Brazil. Rev Bras

Hematol E Hemoter. 2012;34(5):361-366.

Gaytan - Morales F, Alejo - Gonzalez F, Reyes

- Lopez A, et al. Pediatric mature B - cell NHL,

early referral and supportive care problems

in a developing country. Hematol Amst Neth.

;24(1):79-83.

Patte C, Auperin A, Michon J, et al. The

Société Française d’Oncologie Pédiatrique

LMB89 protocol: highly effective multiagent

chemotherapy tailored to the tumor burden and

initial response in 561 unselected children with

B - cell lymphomas and L3 leukemia. Blood.

;97(11):3370-3379.

Gerrard M, Cairo MS, Weston C, et al.

Excellent survival following two courses

of COPAD chemotherapy in children and

adolescents with resected localized B - cell

non - Hodgkin’s lymphoma: results of the FAB/

LMB 96 international study. Br J Haematol.

;141(6):840-847.

Cairo MS, Gerrard M, Sposto R, et al. Results

of a randomized international study of high -

risk central nervous system B non-Hodgkin

lymphoma and B acute lymphoblastic

leukemia in children and adolescents. Blood.

;109(7):2736-2743.

Tsurusawa M, Mori T, Kikuchi A, et al.

Improved treatment results of children with B -

cell non - Hodgkin lymphoma: a report from the

Japanese Pediatric Leukemia/Lymphoma Study

Group B - NHL03 study. Pediatr Blood Cancer.

;61(7):1215-1221.

Rigaud C, Auperin A, Jourdain A, et al. Outcome

of relapse in children and adolescents with B -

cell non - Hodgkin lymphoma and mature acute

leukemia: A report from the French LMB study.

Pediatr Blood Cancer. 2019;66(9):e27873.

Eldar AH, Futerman B, Abrahami G, et al. Burkitt

lymphoma in children: the Israeli experience. J

Pediatr Hematol Oncol. 2009;31(6):428-436.

Reiter A, Klapper W. Recent advances in the

understanding and management of diffuse large

B - cell lymphoma in children. Br J Haematol.

;142(3):329-347.

Perkins SL. Work - up and diagnosis of pediatric

non - Hodgkin’s lymphomas. Pediatr Dev Pathol

Off J Soc Pediatr Pathol Paediatr Pathol Soc.

;3(4):374-390.

Patte C, Auperin A, Gerrard M, et al. Results of

the randomized international FAB/LMB96 trial for

intermediate risk B - cell non - Hodgkin lymphoma

in children and adolescents: it is possible to reduce

treatment for the early responding patients. Blood.

;109(7):2773-2780.

Mukhtar F, Boffetta P, Risch HA, et al. Survival

predictors of Burkitt’s lymphoma in children, adults

and elderly in the United States during 2000 - 2013.

Int J Cancer. 2017;140(7):1494-1502.

Cairo MS, Sposto R, Gerrard M, et

al. Advanced stage, increased lactate

dehydrogenase, and primary site, but not

adolescent age (≥ 15 years), are associated

with an increased risk of treatment failure in

children and adolescents with mature B - cell

non - Hodgkin’s lymphoma: results of the

FAB LMB 96 study. J Clin Oncol Off J Am

Soc Clin Oncol. 2012;30(4):387-393.

Abdel Rahman H, Moussa E, Sedki M. Pediatric

mature B - cell non Hodgkin lymphoma

treatment with LMB - 96 protocol. The Children

Cancer Hospital Egypt experience. Int J Cancer

Ther Oncol. 2015;3:3215.

Pession A, Masetti R, Gaidano G, et al. Risk

evaluation, prophylaxis, and treatment of tumor

lysis syndrome: consensus of an Italian expert

panel. Adv Ther. 2011;28(8):684-697.

Cairo MS, Coiffier B, Reiter A, Younes A, TLS

Expert Panel. Recommendations for the evaluation

of risk and prophylaxis of tumour lysis syndrome

(TLS) in adults and children with malignant

diseases: an expert TLS panel consensus. Br J

Haematol. 2010;149(4):578-586.